Lilly's Symbyax approved for treatment-resistant depression in US
This article was originally published in Scrip
Executive Summary
Lilly's antidepressant Symbyax (a single capsule combination of olanzapine and fluoxetine HCl capsules) has been approved by the US FDA for the acute treatment of treatment-resistant depression, or depression that has not responded adequately to treatment with two previous attempts with antidepressants.